Folie 1

1
Immunosuppression and PSC
Christoph Schramm, Ansgar W. Lohse I.
Medizinische Klinik und Poliklinik Universitätskli
nikum Hamburg-Eppendorf, Hamburg, Germany
2
Immunosuppression and PSC - background

• Up to 10 of PSC patients have overlapping
  features with autoimmune hepatitis (secondary
  AIH)
• Patients with features of autoimmune hepatitis
  benefit from immunosuppressive treatment
• A potential benefit of immunosuppression on early
  stages of PSC is unknown

3
Hypothesis

• Patients with an inflammatory type of PSC /
  secondary autoimmune hepatitis benefit from
  immunosuppression with prednisolone/azathioprine

4
Study Group project

• Retrospective study
• Collect data on patients with PSC who received
  immunosuppression not related to IBD
• Compare long term survival/Ltx to matched control
  population without immunosuppression
• Prospective study
• Define criteria for immunosuppression in PSC,
  e.g. ALT gt 3x ULN, IgG gt 1,2x ULN, histology with
  mHAI gt 6, Scheuer gt 2 (portal/periportal
  activity)
• Prospectively collect data